This study is currently not recruiting participants.

PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBOCONTROLLED

Not Recruiting
99 years or below
All
Phase 2
1 Location

Brief description of study

Reltectimod is a synthetic peptide antagonist that is being developed for treatment of sepsis-associated acute kidney injury (SA-AKI). This study will compare the rates of complete recovery (alive, free of dialysis and return of serum creatinine to less than150% of reference baseline; equivalent to acute kidney disease (AKD) category 0) at Day 14 between the Reltecimod-treated patients and the placebo-treated patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 13 Mar 2019. Study ID: 829686

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.